ARCH Venture Partners outlined plans to target a new $3 billion raise for its latest fund, signaling continued appetite for large-scale biotech venture investment. The vehicle would be ARCH’s 14th fund and would join the ranks of the biggest recent VC efforts supporting clinical-stage and platform-focused biotech. The fundraising plan matters for early-to-mid-stage innovation capacity because large funds can stabilize follow-on financing for companies navigating longer clinical timelines and higher regulatory scrutiny. ARCH’s move also reflects the market’s ongoing split between capital availability in platform plays versus uncertainty in late-stage development. For founders and portfolio teams, the key near-term question is how ARCH’s check size and strategy will map to current pipeline needs across oncology, immunology, and enabling technologies.